Just Released: "Coagulation Disorders Market to 2017"

Sept. 27, 2011 - PRLog -- Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline", provides in-depth analysis of unmet needs, drivers and barriers that impact the global coagulation disorders market. The report analyzes the markets for coagulation disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Market size, annual cost of therapy and treatment usage patterns are forecast until 2016 for the key geographies, as well as the leading therapeutic segments which includes hemophilia A, hemophilia B and von Willebrand Disease. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global coagulation disorders market.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/229791_coagulation_disorders_m...
------------------------------------------------------------

Scope

The scope of this report includes -

* Annualized market data for the coagulation disorders market from 2002 to 2010, forecast forward to 2017.
* Analysis of the leading therapeutic segments, including hemophilia A, hemophilia B, and von Willebrand's disease (vWD).
* Analysis of the coagulation disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
* Market characterization of the coagulation disorders market, including market size, annual cost of therapy and treatment usage patterns.
* Key drivers and barriers that have a significant impact on the market.
* Coverage of pipeline molecules in various phases of drug development.
* Competitive benchmarking of leading companies. The key companies studied in this report are Baxter International Inc, Bayer AG, Novo Nordisk A/S, Pfizer Inc and CSL Behring LLC.
* Key M&A activities and licensing agreements that have taken place between 2004 and 2010 in the global coagulation disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

* Align your product portfolio to the markets with high growth potential.
* Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
* Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with higher efficiency and better safety.
* Develop strategic initiatives by understanding the key focus areas of leading companies.
* Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.


Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 GBI Research Report Guidance
3 Coagulation Disorders Therapeutics Market: Market Overview
3.1 Introduction
3.2 Revenue Forecasts for the Global Coagulation Disorders Market
3.2.1 Revenue
3.2.2 Annual Cost of Therapy
3.2.3 Treatment Usage Pattern
3.3 Coagulation Disorders Market Drivers
3.3.1 Steady Increase in the Prevalence Population, Particularly in the Top Five Countries in Europe
3.3.2 Rapid Uptake of Recombinant Products due to Better Efficacy, Safety and Convenient Dosing
3.3.3 Increase in the Prescription Population due to Patent Expiries of Expensive Biologic Drugs, Making Them More Affordable
3.4 Coagulation Disorders Market Restraints
3.4.1 Low Diagnosed Population as Mild and Moderate Forms of Coagulation Disorders Go Undiagnosed
3.4.2 Patent Expiries of Major Blockbusters Including Kogenate FS, BeneFIX, NovoSeven, and ReFacto Pose a Threat to Leading Players in the Market
3.4.3 Sluggish Growth in the Annual Cost of Therapy for Coagulation Disorders is Expected to Drive Down the Growth Rate
4 Global Coagulation Disorders Market: Geographical Landscape
4.1 Geographical Break-up
4.2 The US
4.2.1 Revenue
4.2.2 Annual Cost of Therapy
4.2.3 Treatment Usage Patterns
4.3 Top Five Countries in Europe
4.3.1 Revenue
4.3.2 Annual Cost of Therapy
4.3.3 Treatment Usage Pattern
4.4 Japan
4.4.1 Revenue
4.4.2 Annual Cost of Therapy
4.4.3 Treatment Usage Patterns
5 Coagulation Disorders Therapeutics Market: Therapeutic Landscape
5.1 Hemophilia A Market
5.1.1 Introduction
5.1.2 Revenue
5.1.3 Annual Cost of Treatment
5.1.4 Treatment Flow Algorithm
5.1.5 Treatment Usage Pattern
5.2 Hemophilia B Market
5.2.1 Introduction
5.2.2 Revenue
5.2.3 Annual Cost of Treatment
5.2.4 Treatment Flow Algorithm
5.2.5 Treatment Usage Pattern
5.3 von Willebrand Disease (vWD) Market
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost of Treatment
5.3.4 Treatment Flow Algorithm
5.3.5 Treatment Usage Pattern
6 Coagulation Disorders Therapeutics Market to 2017: Pipeline Analysis
6.1 Introduction
6.1.1 Research and Development Pipeline - Hemophilia
6.1.2 Research and Development Pipeline - von Willebrand Disease (vWD)
6.2 Profiles of Key Late-Stage Drugs in the Coagulation Disorders Market
6.2.1 NecLip-pdFVIII
6.2.2 Long Acting rFactor VIII
6.2.3 OBI-1
6.2.4 Recombinant Factor IX Fc Fusion Protein (rFIXFc)
6.2.5 NN7008
6.2.6 Human-cl rhFVIII
6.2.7 BAX 326
6.2.8 IB1001
6.2.9 NNC-0156-0000-0009
6.2.10 Biostate
6.2.11 Long Acting rFactor IX
7 Global Coagulation Disorders Market: Competitive Landscape
7.1 Competitive Profiling
7.1.1 Baxter International Inc.
7.1.2 Novo Nordisk A/S
7.1.3 Pfizer Inc.
7.1.4 CSL Behring LLC
7.1.5 Bayer AG
7.1.6 LFB
7.1.7 Grifols
7.1.8 Biotest
7.1.9 Bio Product Laboratory
7.1.10 Octapharma
8 Global Coagulation Disorders Market: Strategic Consolidations
8.1 Overview
8.1.2 Deals by Geography
8.1.3 Deals by Value ($)
9 Global Coagulation Disorders Market: Appendix
9.1 Market Definitions
9.2 Abbreviations

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=2297...

About GBI Research

GBI Research provides industry-leading global business intelligence solutions. Their products and services help companies make better business decisions, win business and position themselves more effectively. GBI Research publishes more than 100 research reports each year across a wide range of industries. These reports draw on in-depth primary and secondary research, databases of proprietary in-house data and high quality analysis from their expert teams. GBI Research employs hundreds of highly qualified Analysts across the US, Europe and Asia.  View more research from GBI Research at http://www.fastmr.com/catalog/publishers.aspx?pubid=1016

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.